Hepatocyte growth factor: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
 
Line 1: Line 1:
<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{Infobox_gene}}
{{PBB_Controls
'''Hepatocyte growth factor''' ('''HGF''') (or '''scatter factor''' ('''SF''') is a [[paracrine]] cellular growth, [[motility]] and [[morphogen|morphogenic factor]]. It is secreted by [[mesenchymal cell]]s and targets and acts primarily upon [[epithelial cell]]s and [[endothelial cell]]s, but also acts on [[haematopoiesis|haemopoietic progenitor cells]] and [[T cell]]s. It has been shown to have a major role in embryonic organ development, specifically in [[myogenesis]], in adult organ regeneration, and in wound healing.<ref>{{cite book | title=Proteoglycans: structure, biology and molecular interactions | author=Gallagher, J.T., Lyon, M. | chapter=Molecular structure of Heparan Sulfate and interactions with growth factors and morphogens | editor=Iozzo, M, V. | year=2000 | publisher=Marcel Dekker Inc. New York, New York | pages=27–59}}</ref>
| update_page = yes
| require_manual_inspection = no
| update_protein_box = yes
| update_summary = yes
| update_citations = yes
}}


<!-- The GNF_Protein_box is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
== Function ==
{{GNF_Protein_box
Hepatocyte growth factor regulates cell growth, cell motility, and [[morphogenesis]] by activating a [[tyrosine kinase]] signaling cascade after binding to the proto-oncogenic [[c-Met]] receptor.<ref name="pmid1846706">{{cite journal | vauthors = Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA | title = Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product | journal = Science | volume = 251 | issue = 4995 | pages = 802–4 | date = February 1991 | pmid = 1846706 | doi = 10.1126/science.1846706 }}</ref><ref>{{cite journal | vauthors = Johnson M, Koukoulis G, Matsumoto K, Nakamura T, Iyer A | title = Hepatocyte growth factor induces proliferation and morphogenesis in nonparenchymal epithelial liver cells | journal = Hepatology | volume = 17 | issue = 6 | pages = 1052–61 | date = June 1993 | pmid = 8514254 | doi = 10.1016/0270-9139(93)90122-4 }}</ref> Hepatocyte growth factor is secreted by [[mesenchymal cell]]s and acts as a multi-functional [[cytokine]] on cells of mainly epithelial origin. Its ability to stimulate [[mitogenesis]], cell motility, and matrix invasion gives it a central role in [[angiogenesis]], [[tumorogenesis]], and tissue regeneration.<ref name = "entrez" />
| image = PBB_Protein_HGF_image.jpg
| image_source = [[Protein_Data_Bank|PDB]] rendering based on 1bht.
| PDB = {{PDB2|1bht}}, {{PDB2|1gmn}}, {{PDB2|1gmo}}, {{PDB2|1gp9}}, {{PDB2|1nk1}}, {{PDB2|1shy}}, {{PDB2|1si5}}, {{PDB2|2hgf}}
| Name = Hepatocyte growth factor (hepapoietin A; scatter factor)
| HGNCid = 4893
| Symbol = HGF
| AltSymbols =; F-TCF; HGFB; HPTA; SF
| OMIM = 142409
| ECnumber =
| Homologene = 503
| MGIid = 96079
| GeneAtlas_image1 = PBB_GE_HGF_209960_at_tn.png
| GeneAtlas_image2 = PBB_GE_HGF_209961_s_at_tn.png
| GeneAtlas_image3 = PBB_GE_HGF_210998_s_at_tn.png
| Function = {{GNF_GO|id=GO:0004252 |text = serine-type endopeptidase activity}} {{GNF_GO|id=GO:0005509 |text = calcium ion binding}} {{GNF_GO|id=GO:0005515 |text = protein binding}} {{GNF_GO|id=GO:0008083 |text = growth factor activity}}
| Component = {{GNF_GO|id=GO:0005575 |text = cellular_component}}
| Process = {{GNF_GO|id=GO:0000187 |text = activation of MAPK activity}} {{GNF_GO|id=GO:0000902 |text = cell morphogenesis}} {{GNF_GO|id=GO:0006508 |text = proteolysis}} {{GNF_GO|id=GO:0006916 |text = anti-apoptosis}} {{GNF_GO|id=GO:0007067 |text = mitosis}} {{GNF_GO|id=GO:0007596 |text = blood coagulation}} {{GNF_GO|id=GO:0048012 |text = hepatocyte growth factor receptor signaling pathway}} {{GNF_GO|id=GO:0051450 |text = myoblast proliferation}}
| Orthologs = {{GNF_Ortholog_box
    | Hs_EntrezGene = 3082
    | Hs_Ensembl = ENSG00000019991
    | Hs_RefseqProtein = NP_000592
    | Hs_RefseqmRNA = NM_000601
    | Hs_GenLoc_db = 
    | Hs_GenLoc_chr = 7
    | Hs_GenLoc_start = 81166258
    | Hs_GenLoc_end = 81237388
    | Hs_Uniprot = P14210
    | Mm_EntrezGene = 15234
    | Mm_Ensembl = ENSMUSG00000028864
    | Mm_RefseqmRNA = NM_010427
    | Mm_RefseqProtein = NP_034557
    | Mm_GenLoc_db = 
    | Mm_GenLoc_chr = 5
    | Mm_GenLoc_start = 16065374
    | Mm_GenLoc_end = 16131263
    | Mm_Uniprot = O55027
  }}
}}
'''Hepatocyte growth factor/scatter factor''' (HGF/SF) is a [[paracrine]] cellular growth, motility and [[morphogen|morphogenic factor]]. It is secreted by [[mesenchymal cell]]s and targets and acts primarily upon [[epithelial cell]]s and [[endothelial cell]]s, but also acts on [[haematopoiesis|haemopoietic progenitor cells]]. It has been shown to have a major role in embryonic organ development, in adult organ regeneration and in wound healing.<ref>{{cite book | title=Proteoglycans: structure, biology and molecular interactions | author=Gallagher, J.T., Lyon, M. | chapter=Molecular structure of Heparan Sulfate and interactions with growth factors and morphogens | editor=Iozzo, M, V. | year=2000 | publisher=Marcel Dekker Inc. New York, New York | pages=27-59}}</ref>


<!-- The PBB_Summary template is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
== Structure ==
{{PBB_Summary
It is secreted as a single inactive polypeptide and is cleaved by serine proteases into a 69-kDa alpha-chain and 34-kDa beta-chain. A disulfide bond between the alpha and beta chains produces the active, heterodimeric molecule. The protein belongs to the [[plasminogen]] subfamily of S1 peptidases but has no detectable [[protease]] activity.<ref name = "entrez" >{{cite web | title = Entrez Gene: HGF hepatocyte growth factor (hepapoietin A; scatter factor)| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=3082| accessdate = }}</ref>
| section_title =  
| summary_text = Hepatocyte growth factor regulates cell growth, cell motility, and morphogenesis by activating a tyrosine kinase signaling cascade after binding to the proto-oncogenic c-Met receptor. Hepatocyte growth factor is secreted by mesenchymal cells and acts as a multi-functional cytokine on cells of mainly epithelial origin. Its ability to stimulate mitogenesis, cell motility, and matrix invasion gives it a central role in angiogenesis, tumorogenesis, and tissue regeneration. It is secreted as a single inactive polypeptide and is cleaved by serine proteases into a 69-kDa alpha-chain and 34-kDa beta-chain. A disulfide bond between the alpha and beta chains produces the active, heterodimeric molecule. The protein belongs to the plasminogen subfamily of S1 peptidases but has no detectable protease activity. Alternative splicing of this gene produces multiple transcript variants encoding different isoforms.<ref>{{cite web | title = Entrez Gene: HGF hepatocyte growth factor (hepapoietin A; scatter factor)| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=3082| accessdate = }}</ref>
}}


==References==
== Clinical significance ==
{{reflist|2}}
[[Human HGF plasmid DNA therapy]] of [[cardiomyocytes]] is being examined as a potential treatment for [[coronary artery disease]] as well as treatment for the damage that occurs to the heart after [[myocardial infarction]].<ref name=YangZhang2008>{{cite journal | vauthors = Yang ZJ, Zhang YR, Chen B, Zhang SL, Jia EZ, Wang LS, Zhu TB, Li CJ, Wang H, Huang J, Cao KJ, Ma WZ, Wu B, Wang LS, Wu CT | title = Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease | journal = Molecular Biology Reports | volume = 36 | issue = 6 | pages = 1323–9 | date = July 2009 | pmid = 18649012 | pmc =  | doi = 10.1007/s11033-008-9315-3 }}</ref><ref name=HahnPyun2011>{{cite journal | vauthors = Hahn W, Pyun WB, Kim DS, Yoo WS, Lee SD, Won JH, Shin GJ, Kim JM, Kim S | title = Enhanced cardioprotective effects by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA in a rat ischemic heart disease model | journal = The Journal of Gene Medicine | volume = 13 | issue = 10 | pages = 549–55 | date = October 2011 | pmid = 21898720 | pmc =  | doi = 10.1002/jgm.1603 }}</ref>
==Further reading==
As well as the well-characterised effects of HGF on [[epithelial cell]]s, [[endothelial cell]]s and [[haemopoietic progenitor cell]]s, HGF also regulates the chemotaxis of T cells into heart tissue. Binding of HGF by c-Met, expressed on T cells, causes the upregulation of c-Met, [[CXCR3]], and [[CCR4]] which in turn imbues them with the ability to migrate into heart tissue.<ref name="pmid26070483">{{cite journal | vauthors = Komarowska I, Coe D, Wang G, Haas R, Mauro C, Kishore M, Cooper D, Nadkarni S, Fu H, Steinbruchel DA, Pitzalis C, Anderson G, Bucy P, Lombardi G, Breckenridge R, Marelli-Berg FM | title = Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release | journal = Immunity | volume = 42 | issue = 6 | pages = 1087–99 | date = September 2016 | pmid = 26070483 | pmc = 4510150 | doi = 10.1016/j.immuni.2015.05.014 }}</ref> HGF also promotes angiogenesis in ischemia injury. <ref>{{cite journal | vauthors = Chang HK, Kim PH, Cho, HM, Yum, SY, Choi, YJ, Lee D, Kang I, Kang KS, Jang G, Cho JY| title = Inducible HGF-secreting Human Umbilical Cord Blood-derived MSCs Produced via TALEN-mediated Genome Editing Promoted Angiogenesis | journal = Molecular Therapy | volume = 24 | issue = 9 | pages = 1644-54 | date = Sep 2016 | pmid = 27434585 | pmc = 5113099 | doi = 10.1038/mt.2016.120 }}</ref>
{{refbegin | 2}}
HGF may further play a role as an indicator for prognosis of chronicity for [[Chikungunya]] virus induced [[arthralgia]]. High HGF levels correlate with high rates of recovery.<ref name="pmid21288813">{{cite journal | vauthors = Chow A, Her Z, Ong EK, Chen JM, Dimatatac F, Kwek DJ, Barkham T, Yang H, Rénia L, Leo YS, Ng LF | title = Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor | journal = The Journal of Infectious Diseases | volume = 203 | issue = 2 | pages = 149–57 | date = January 2011 | pmid = 21288813 | pmc = 3071069 | doi = 10.1093/infdis/jiq042 }}</ref>
{{PBB_Further_reading
 
| citations =  
Excessive local expression of HGF in the [[breast]]s has been implicated in [[macromastia]].<ref name="ZhongWang2014">{{cite journal | vauthors = Zhong A, Wang G, Yang J, Xu Q, Yuan Q, Yang Y, Xia Y, Guo K, Horch RE, Sun J | title = Stromal-epithelial cell interactions and alteration of branching morphogenesis in macromastic mammary glands | journal = Journal of Cellular and Molecular Medicine | volume = 18 | issue = 7 | pages = 1257–66 | date = July 2014 | pmid = 24720804 | doi = 10.1111/jcmm.12275 | pmc=4124011}}</ref> HGF is also importantly involved in normal [[mammary gland]] development.<ref name="pmid7555716">{{vcite2 journal | vauthors = Niranjan B, Buluwela L, Yant J, Perusinghe N, Atherton A, Phippard D, Dale T, Gusterson B, Kamalati T | title = HGF/SF: a potent cytokine for mammary growth, morphogenesis and development | journal = Development | volume = 121 | issue = 9 | pages = 2897–908 | year = 1995 | pmid = 7555716 | doi = | url = }}</ref><ref name="pmid10219907">{{vcite2 journal | vauthors = Kamalati T, Niranjan B, Yant J, Buluwela L | title = HGF/SF in mammary epithelial growth and morphogenesis: in vitro and in vivo models | journal = J Mammary Gland Biol Neoplasia | volume = 4 | issue = 1 | pages = 69–77 | year = 1999 | pmid = 10219907 | doi = | url = }}</ref>
*{{cite journal | author=Nakamura T |title=Structure and function of hepatocyte growth factor. |journal=Prog. Growth Factor Res. |volume=3 |issue= 1 |pages= 67-85 |year= 1992 |pmid= 1838014 |doi= }}
 
*{{cite journal | author=Ware LB, Matthay MA |title=Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. |journal=Am. J. Physiol. Lung Cell Mol. Physiol. |volume=282 |issue= 5 |pages= L924-40 |year= 2002 |pmid= 11943656 |doi= 10.1152/ajplung.00439.2001 }}
HGF has been implicated in a variety of [[cancer]]s, including of the [[lung]]s, [[pancreas]], [[thyroid]], [[Large intestine|colon]], and [[breast]].<ref name="ZieglerPierce2012">{{cite book|author1=Thomas R. Ziegler|author2=Glenn F. Pierce|author3=David N. Herndon|title=Growth Factors and Wound Healing: Basic Science and Potential Clinical Applications|url=https://books.google.com/books?id=5ct9BwAAQBAJ&pg=PA311|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4612-1876-0|pages=311–}}</ref><ref name="pmid15767355">{{cite journal | vauthors = Sheen-Chen SM, Liu YW, Eng HL, Chou FF | title = Serum levels of hepatocyte growth factor in patients with breast cancer | journal = Cancer Epidemiology, Biomarkers & Prevention | volume = 14 | issue = 3 | pages = 715–7 | date = March 2005 | pmid = 15767355 | doi = 10.1158/1055-9965.EPI-04-0340 }}</ref><ref name="pmid21934211">{{cite journal | vauthors = El-Attar HA, Sheta MI | title = Hepatocyte growth factor profile with breast cancer | journal = Indian Journal of Pathology & Microbiology | volume = 54 | issue = 3 | pages = 509–13 | year = 2011 | pmid = 21934211 | doi = 10.4103/0377-4929.85083 }}</ref>
*{{cite journal | author=Funakoshi H, Nakamura T |title=Hepatocyte growth factor: from diagnosis to clinical applications. |journal=Clin. Chim. Acta |volume=327 |issue= 1-2 |pages= 1-23 |year= 2003 |pmid= 12482615 |doi= }}
 
*{{cite journal | author=Skibinski G |title=The role of hepatocyte growth factor/c-met interactions in the immune system. |journal=Arch. Immunol. Ther. Exp. (Warsz.) |volume=51 |issue= 5 |pages= 277-82 |year= 2004 |pmid= 14626426 |doi=  }}
=== Circulating plasma levels ===
*{{cite journal | author=Kalluri R, Neilson EG |title=Epithelial-mesenchymal transition and its implications for fibrosis. |journal=J. Clin. Invest. |volume=112 |issue= 12 |pages= 1776-84 |year= 2004 |pmid= 14679171 |doi= 10.1172/JCI200320530 }}
Plasma from patients with advanced heart failure presents increased levels of HGF, which correlates with a negative prognosis and a high risk of mortality.<ref>{{cite journal | vauthors = Richter B, Koller L, Hohensinner PJ, Zorn G, Brekalo M, Berger R, Mörtl D, Maurer G, Pacher R, Huber K, Wojta J, Hülsmann M, Niessner A | title = A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure | journal = International Journal of Cardiology | volume = 168 | issue = 2 | pages = 1251–7 | date = September 2013 | pmid = 23218577 | doi = 10.1016/j.ijcard.2012.11.052 }}</ref><ref>{{cite journal | vauthors = Rychli K, Richter B, Hohensinner PJ, Kariem Mahdy A, Neuhold S, Zorn G, Berger R, Mörtl D, Huber K, Pacher R, Wojta J, Niessner A, Hülsmann M | title = Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure | journal = Heart | volume = 97 | issue = 14 | pages = 1158–63 | date = July 2011 | pmid = 21572126 | doi = 10.1136/hrt.2010.220228 }}</ref> Circulating HGF has been also identified as a prognostic marker of severity in patients suffering from hypertension.<ref name="ReferenceB">{{cite journal | vauthors = Nakamura S, Morishita R, Moriguchi A, Yo Y, Nakamura Y, Hayashi S, Matsumoto K, Matsumoto K, Nakamura T, Higaki J, Ogihara T | title = Hepatocyte growth factor as a potential index of complication in diabetes mellitus | journal = Journal of Hypertension | volume = 16 | issue = 12 Pt 2 | pages = 2019–26 | date = December 1998 | pmid = 9886892 | doi = 10.1291/hypres.22.161 }}</ref><ref name="ReferenceB"/> Circulating HGF has been also suggested as a precocious biomarker for the acute phase of bowel inflammation.<ref>{{cite journal | vauthors = Sorour AE, Lönn J, Nakka SS, Nayeri T, Nayeri F | title = Evaluation of hepatocyte growth factor as a local acute phase response marker in the bowel: the clinical impact of a rapid diagnostic test for immediate identification of acute bowel inflammation | journal = Cytokine | volume = 71 | issue = 1 | pages = 8–15 | date = January 2015 | pmid = 25174881 | doi = 10.1016/j.cyto.2014.07.255 }}</ref>
*{{cite journal | author=Hurle RA, Davies G, Parr C, ''et al.'' |title=Hepatocyte growth factor/scatter factor and prostate cancer: a review. |journal=Histol. Histopathol. |volume=20 |issue= 4 |pages= 1339-49 |year= 2006 |pmid= 16136515 |doi= }}
 
*{{cite journal | author=Kemp LE, Mulloy B, Gherardi E |title=Signalling by HGF/SF and Met: the role of heparan sulphate co-receptors. |journal=Biochem. Soc. Trans. |volume=34 |issue= Pt 3 |pages= 414-7 |year= 2006 |pmid= 16709175 |doi= 10.1042/BST0340414 }}
== Pharmacokinetics ==
}}
[[Exogenous]] HGF administered by [[intravenous injection]] is cleared rapidly from circulation by the [[liver]], with a [[half-life]] of approximately 4 minutes.<ref name="Yang2001">{{cite journal | vauthors = Yang J, Chen S, Huang L, Michalopoulos GK, Liu Y | title = Sustained expression of naked plasmid DNA encoding hepatocyte growth factor in mice promotes liver and overall body growth | journal = Hepatology | volume = 33 | issue = 4 | pages = 848–59 | date = April 2001 | pmid = 11283849 | pmc = 1821076 | doi = 10.1053/jhep.2001.23438 }}</ref><ref name="pmid8450646">{{cite journal | vauthors = Appasamy R, Tanabe M, Murase N, Zarnegar R, Venkataramanan R, Van Thiel DH, Michalopoulos GK | title = Hepatocyte growth factor, blood clearance, organ uptake, and biliary excretion in normal and partially hepatectomized rats | journal = Laboratory Investigation; A Journal of Technical Methods and Pathology | volume = 68 | issue = 3 | pages = 270–6 | date = March 1993 | pmid = 8450646 | doi =  }}</ref><ref name="KatoLiu1994">{{cite journal | vauthors = Kato Y, Liu KX, Nakamura T, Sugiyama Y | title = Heparin-hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity | journal = Hepatology | volume = 20 | issue = 2 | pages = 417–24 | date = August 1994 | pmid = 8045504 | doi = 10.1002/hep.1840200223 }}</ref><ref name="YuYao2007">{{cite journal | vauthors = Yu Y, Yao AH, Chen N, Pu LY, Fan Y, Lv L, Sun BC, Li GQ, Wang XH | title = Mesenchymal stem cells over-expressing hepatocyte growth factor improve small-for-size liver grafts regeneration | journal = Molecular Therapy | volume = 15 | issue = 7 | pages = 1382–9 | date = July 2007 | pmid = 17519892 | doi = 10.1038/sj.mt.6300202 }}</ref>
 
==Modulators==
[[Dihexa]] is an orally active, centrally penetrant [[small-molecule]] compound that directly binds to HGF and potentiates its ability to activate its receptor, c-Met.<ref name="BenoistKawas2014">{{cite journal | vauthors = Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW | title = The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 351 | issue = 2 | pages = 390–402 | date = November 2014 | pmid = 25187433 | pmc = 4201273 | doi = 10.1124/jpet.114.218735 }}</ref> It is a strong inducer of [[neurogenesis]] and is being studied for the potential treatment of [[Alzheimer's disease]] and [[Parkinson's disease]].<ref name="pmid25649658">{{cite journal | vauthors = Wright JW, Harding JW | title = The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease | journal = Journal of Alzheimer's Disease | volume = 45 | issue = 4 | pages = 985–1000 | year = 2015 | pmid = 25649658 | doi = 10.3233/JAD-142814 }}</ref><ref name="WrightKawas2015">{{cite journal | vauthors = Wright JW, Kawas LH, Harding JW | title = The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases | journal = Progress in Neurobiology | volume = 125 | pages = 26–46 | date = February 2015 | pmid = 25455861 | doi = 10.1016/j.pneurobio.2014.11.004 }}</ref>
 
== Interactions ==
Hepatocyte growth factor has been shown to [[Protein-protein interaction|interact]] with the protein product of the c-Met oncogene, identified as the HGF receptor ([[c-Met|HGFR]]).<ref name="pmid1846706"/><ref name="pmid8380735">{{cite journal | vauthors = Comoglio PM | title = Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells | journal = Exs | volume = 65 | issue =  | pages = 131–65 | year = 1993 | pmid = 8380735 | doi =  }}</ref><ref name="pmid1655405">{{cite journal | vauthors = Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK | title = Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor | journal = The EMBO Journal | volume = 10 | issue = 10 | pages = 2867–78 | date = October 1991 | pmid = 1655405 | pmc = 452997 | doi =  }}</ref> Both overexpression of the Met/HGFR receptor protein and [[Autocrine signalling|autocrine]] activation of Met/HGFR by simultaneous expression of the hepatocyte growth factor ligand have been implicated in oncogenesis.<ref>{{cite journal | vauthors = Johnson M, Koukoulis G, Kochhar K, Kubo C, Nakamura T, Iyer A | title = Selective tumorigenesis in non-parenchymal liver epithelial cell lines by hepatocyte growth factor transfection | journal = Cancer Letters | volume = 96 | issue = 1 | pages = 37–48 | date = September 1995 | pmid = 7553606 | doi = 10.1016/0304-3835(95)03915-j }}</ref><ref>{{cite journal | vauthors = Kochhar KS, Johnson ME, Volpert O, Iyer AP | title = Evidence for autocrine basis of transformation in NIH-3T3 cells transfected with met/HGF receptor gene | journal = Growth Factors | volume = 12 | issue = 4 | pages = 303–13 | date = 1995 | pmid = 8930021 | doi = 10.3109/08977199509028968 }}</ref>
Hepatocyte growth factor interacts with the sulfated glycosaminoglycans heparan sulfate and dermatan sulfate.<ref name="ReferenceA">{{cite journal | vauthors = Lyon M, Deakin JA, Gallagher JT | title = The mode of action of heparan and dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor | journal = The Journal of Biological Chemistry | volume = 277 | issue = 2 | pages = 1040–6 | date = January 2002 | pmid = 11689562 | doi = 10.1074/jbc.M107506200 }}</ref><ref>{{cite journal | vauthors = Lyon M, Deakin JA, Rahmoune H, Fernig DG, Nakamura T, Gallagher JT | title = Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate | journal = J Biol Chem | volume = 273 | issue = 1 | pages = 271–8. | date = Jan 1998 | PMID = 9417075 | doi = 10.1074/jbc.273.1.271 | url = http://www.jbc.org/content/273/1/271.long}}</ref> The interaction with heparan suflate allows hepatocyte growth factor to form a complex with c-Met that is able to transduce intracellular signals leading to cell division and cell migration.<ref name="ReferenceA"/><ref>{{cite journal | vauthors = Sergeant N, Lyon M, Rudland PS, Fernig DG, Delehedde M | title = Stimulation of DNA synthesis and cell proliferation of human mammary myoepithelial-like cells by hepatocyte growth factor/scatter factor depends on heparan sulfate proteoglycans and sustained phosphorylation of mitogen-activated protein kinases p42/44 | journal = The Journal of Biological Chemistry | volume = 275 | issue = 22 | pages = 17094–9 | date = June 2000 | pmid = 10747885 | doi = 10.1074/jbc.M000237200 }}</ref>
 
== See also ==
* [[Epidermal growth factor]]
* [[Insulin-like growth factor 1]]
* [[Epithelial–mesenchymal transition]]
* [[Madin-Darby Canine Kidney Cells]]
 
== References ==
{{reflist|33em}}
 
== Further reading ==
{{refbegin|33em}}
* {{cite journal  |vauthors=Michalopoulos GK, Zarnegar R |title=Hepatocyte Growth Factor |journal=Hepatology |volume=15 |issue=1 |pages= 149–54 |year= 1992 |doi=10.1002/hep.1840150125 }}
* {{cite journal | vauthors = Nakamura T | title = Structure and function of hepatocyte growth factor | journal = Progress in Growth Factor Research | volume = 3 | issue = 1 | pages = 67–85 | year = 1992 | pmid = 1838014 | doi = 10.1016/0955-2235(91)90014-U }}
* {{cite journal | vauthors = Ware LB, Matthay MA | title = Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair | journal = American Journal of Physiology. Lung Cellular and Molecular Physiology | volume = 282 | issue = 5 | pages = L924-40 | date = May 2002 | pmid = 11943656 | doi = 10.1152/ajplung.00439.2001 }}
* {{cite journal | vauthors = Funakoshi H, Nakamura T | title = Hepatocyte growth factor: from diagnosis to clinical applications | journal = Clinica Chimica Acta; International Journal of Clinical Chemistry | volume = 327 | issue = 1–2 | pages = 1–23 | date = January 2003 | pmid = 12482615 | doi = 10.1016/S0009-8981(02)00302-9 }}
* {{cite journal | vauthors = Skibinski G | title = The role of hepatocyte growth factor/c-met interactions in the immune system | journal = Archivum Immunologiae Et Therapiae Experimentalis | volume = 51 | issue = 5 | pages = 277–82 | year = 2004 | pmid = 14626426 | doi =  }}
* {{cite journal | vauthors = Kalluri R, Neilson EG | title = Epithelial-mesenchymal transition and its implications for fibrosis | journal = The Journal of Clinical Investigation | volume = 112 | issue = 12 | pages = 1776–84 | date = December 2003 | pmid = 14679171 | pmc = 297008 | doi = 10.1172/JCI20530 }}
* {{cite journal | vauthors = Hurle RA, Davies G, Parr C, Mason MD, Jenkins SA, Kynaston HG, Jiang WG | title = Hepatocyte growth factor/scatter factor and prostate cancer: a review | journal = Histology and Histopathology | volume = 20 | issue = 4 | pages = 1339–49 | date = October 2005 | pmid = 16136515 | doi = 10.14670/HH-20.1339 }}
* {{cite journal | vauthors = Kemp LE, Mulloy B, Gherardi E | title = Signalling by HGF/SF and Met: the role of heparan sulphate co-receptors | journal = Biochemical Society Transactions | volume = 34 | issue = Pt 3 | pages = 414–7 | date = June 2006 | pmid = 16709175 | doi = 10.1042/BST0340414 }}
{{refend}}
{{refend}}


==See also==
== External links ==
* [[growth factor]]
* {{MeshName|Hepatocyte+growth+factor}}
* hepatocyte growth factor receptor ([[HGFR]])
* [http://atlasgeneticsoncology.org/Genes/HGFID385ch7q21.html Hepatocyte growth factor] on the [[Atlas of Genetics and Cytogenetics in Oncology and Haematology|Atlas of Genetics and Oncology]]
* UCSD Signaling Gateway Molecule Page on [http://www.signaling-gateway.org/molecule/query;jsessionid=91a63736ae2def075573341606d54c19bbd937b3321a22673dceb6cfb49c4f1f?afcsid=A004032 HGF]


==External links==
{{PDB Gallery|geneid=3082}}
* {{MeshName|Hepatocyte+growth+factor}}
{{Intercellular signaling peptides and proteins}}
{{Growth factors}}
{{Growth factor receptor modulators}}


[[Category:Growth factors]]
[[Category:Growth factors]]
[[Category:Developmental biology]]
[[Category:Developmental genes and proteins]]
[[Category:Cytokines]]
[[Category:Cytokines]]
 
[[Category:World Anti-Doping Agency prohibited substances]]
{{biochem-stub}}
{{Cytokines}}
{{WikiDoc Sources}}

Revision as of 11:28, 7 November 2017

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez

n/a

n/a

Ensembl

n/a

n/a

UniProt

n/a

n/a

RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration, and in wound healing.[1]

Function

Hepatocyte growth factor regulates cell growth, cell motility, and morphogenesis by activating a tyrosine kinase signaling cascade after binding to the proto-oncogenic c-Met receptor.[2][3] Hepatocyte growth factor is secreted by mesenchymal cells and acts as a multi-functional cytokine on cells of mainly epithelial origin. Its ability to stimulate mitogenesis, cell motility, and matrix invasion gives it a central role in angiogenesis, tumorogenesis, and tissue regeneration.[4]

Structure

It is secreted as a single inactive polypeptide and is cleaved by serine proteases into a 69-kDa alpha-chain and 34-kDa beta-chain. A disulfide bond between the alpha and beta chains produces the active, heterodimeric molecule. The protein belongs to the plasminogen subfamily of S1 peptidases but has no detectable protease activity.[4]

Clinical significance

Human HGF plasmid DNA therapy of cardiomyocytes is being examined as a potential treatment for coronary artery disease as well as treatment for the damage that occurs to the heart after myocardial infarction.[5][6] As well as the well-characterised effects of HGF on epithelial cells, endothelial cells and haemopoietic progenitor cells, HGF also regulates the chemotaxis of T cells into heart tissue. Binding of HGF by c-Met, expressed on T cells, causes the upregulation of c-Met, CXCR3, and CCR4 which in turn imbues them with the ability to migrate into heart tissue.[7] HGF also promotes angiogenesis in ischemia injury. [8] HGF may further play a role as an indicator for prognosis of chronicity for Chikungunya virus induced arthralgia. High HGF levels correlate with high rates of recovery.[9]

Excessive local expression of HGF in the breasts has been implicated in macromastia.[10] HGF is also importantly involved in normal mammary gland development.[11][12]

HGF has been implicated in a variety of cancers, including of the lungs, pancreas, thyroid, colon, and breast.[13][14][15]

Circulating plasma levels

Plasma from patients with advanced heart failure presents increased levels of HGF, which correlates with a negative prognosis and a high risk of mortality.[16][17] Circulating HGF has been also identified as a prognostic marker of severity in patients suffering from hypertension.[18][18] Circulating HGF has been also suggested as a precocious biomarker for the acute phase of bowel inflammation.[19]

Pharmacokinetics

Exogenous HGF administered by intravenous injection is cleared rapidly from circulation by the liver, with a half-life of approximately 4 minutes.[20][21][22][23]

Modulators

Dihexa is an orally active, centrally penetrant small-molecule compound that directly binds to HGF and potentiates its ability to activate its receptor, c-Met.[24] It is a strong inducer of neurogenesis and is being studied for the potential treatment of Alzheimer's disease and Parkinson's disease.[25][26]

Interactions

Hepatocyte growth factor has been shown to interact with the protein product of the c-Met oncogene, identified as the HGF receptor (HGFR).[2][27][28] Both overexpression of the Met/HGFR receptor protein and autocrine activation of Met/HGFR by simultaneous expression of the hepatocyte growth factor ligand have been implicated in oncogenesis.[29][30] Hepatocyte growth factor interacts with the sulfated glycosaminoglycans heparan sulfate and dermatan sulfate.[31][32] The interaction with heparan suflate allows hepatocyte growth factor to form a complex with c-Met that is able to transduce intracellular signals leading to cell division and cell migration.[31][33]

See also

References

  1. ↑ Gallagher, J.T., Lyon, M. (2000). "Molecular structure of Heparan Sulfate and interactions with growth factors and morphogens". In Iozzo, M, V. Proteoglycans: structure, biology and molecular interactions. Marcel Dekker Inc. New York, New York. pp. 27–59.
  2. ↑ 2.0 2.1 Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA (February 1991). "Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product". Science. 251 (4995): 802–4. doi:10.1126/science.1846706. PMID 1846706.
  3. ↑ Johnson M, Koukoulis G, Matsumoto K, Nakamura T, Iyer A (June 1993). "Hepatocyte growth factor induces proliferation and morphogenesis in nonparenchymal epithelial liver cells". Hepatology. 17 (6): 1052–61. doi:10.1016/0270-9139(93)90122-4. PMID 8514254.
  4. ↑ 4.0 4.1 "Entrez Gene: HGF hepatocyte growth factor (hepapoietin A; scatter factor)".
  5. ↑ Yang ZJ, Zhang YR, Chen B, Zhang SL, Jia EZ, Wang LS, Zhu TB, Li CJ, Wang H, Huang J, Cao KJ, Ma WZ, Wu B, Wang LS, Wu CT (July 2009). "Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease". Molecular Biology Reports. 36 (6): 1323–9. doi:10.1007/s11033-008-9315-3. PMID 18649012.
  6. ↑ Hahn W, Pyun WB, Kim DS, Yoo WS, Lee SD, Won JH, Shin GJ, Kim JM, Kim S (October 2011). "Enhanced cardioprotective effects by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA in a rat ischemic heart disease model". The Journal of Gene Medicine. 13 (10): 549–55. doi:10.1002/jgm.1603. PMID 21898720.
  7. ↑ Komarowska I, Coe D, Wang G, Haas R, Mauro C, Kishore M, Cooper D, Nadkarni S, Fu H, Steinbruchel DA, Pitzalis C, Anderson G, Bucy P, Lombardi G, Breckenridge R, Marelli-Berg FM (September 2016). "Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release". Immunity. 42 (6): 1087–99. doi:10.1016/j.immuni.2015.05.014. PMC 4510150. PMID 26070483.
  8. ↑ Chang HK, Kim PH, Cho, HM, Yum, SY, Choi, YJ, Lee D, Kang I, Kang KS, Jang G, Cho JY (Sep 2016). "Inducible HGF-secreting Human Umbilical Cord Blood-derived MSCs Produced via TALEN-mediated Genome Editing Promoted Angiogenesis". Molecular Therapy. 24 (9): 1644–54. doi:10.1038/mt.2016.120. PMC 5113099. PMID 27434585.
  9. ↑ Chow A, Her Z, Ong EK, Chen JM, Dimatatac F, Kwek DJ, Barkham T, Yang H, Rénia L, Leo YS, Ng LF (January 2011). "Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor". The Journal of Infectious Diseases. 203 (2): 149–57. doi:10.1093/infdis/jiq042. PMC 3071069. PMID 21288813.
  10. ↑ Zhong A, Wang G, Yang J, Xu Q, Yuan Q, Yang Y, Xia Y, Guo K, Horch RE, Sun J (July 2014). "Stromal-epithelial cell interactions and alteration of branching morphogenesis in macromastic mammary glands". Journal of Cellular and Molecular Medicine. 18 (7): 1257–66. doi:10.1111/jcmm.12275. PMC 4124011. PMID 24720804.
  11. ↑ Niranjan B, Buluwela L, Yant J, Perusinghe N, Atherton A, Phippard D, et al. (1995). "HGF/SF: a potent cytokine for mammary growth, morphogenesis and development". Development. 121 (9): 2897–908. PMID 7555716.
  12. ↑ Kamalati T, Niranjan B, Yant J, Buluwela L (1999). "HGF/SF in mammary epithelial growth and morphogenesis: in vitro and in vivo models". J Mammary Gland Biol Neoplasia. 4 (1): 69–77. PMID 10219907.
  13. ↑ Thomas R. Ziegler; Glenn F. Pierce; David N. Herndon (6 December 2012). Growth Factors and Wound Healing: Basic Science and Potential Clinical Applications. Springer Science & Business Media. pp. 311–. ISBN 978-1-4612-1876-0.
  14. ↑ Sheen-Chen SM, Liu YW, Eng HL, Chou FF (March 2005). "Serum levels of hepatocyte growth factor in patients with breast cancer". Cancer Epidemiology, Biomarkers & Prevention. 14 (3): 715–7. doi:10.1158/1055-9965.EPI-04-0340. PMID 15767355.
  15. ↑ El-Attar HA, Sheta MI (2011). "Hepatocyte growth factor profile with breast cancer". Indian Journal of Pathology & Microbiology. 54 (3): 509–13. doi:10.4103/0377-4929.85083. PMID 21934211.
  16. ↑ Richter B, Koller L, Hohensinner PJ, Zorn G, Brekalo M, Berger R, Mörtl D, Maurer G, Pacher R, Huber K, Wojta J, Hülsmann M, Niessner A (September 2013). "A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure". International Journal of Cardiology. 168 (2): 1251–7. doi:10.1016/j.ijcard.2012.11.052. PMID 23218577.
  17. ↑ Rychli K, Richter B, Hohensinner PJ, Kariem Mahdy A, Neuhold S, Zorn G, Berger R, Mörtl D, Huber K, Pacher R, Wojta J, Niessner A, Hülsmann M (July 2011). "Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure". Heart. 97 (14): 1158–63. doi:10.1136/hrt.2010.220228. PMID 21572126.
  18. ↑ 18.0 18.1 Nakamura S, Morishita R, Moriguchi A, Yo Y, Nakamura Y, Hayashi S, Matsumoto K, Matsumoto K, Nakamura T, Higaki J, Ogihara T (December 1998). "Hepatocyte growth factor as a potential index of complication in diabetes mellitus". Journal of Hypertension. 16 (12 Pt 2): 2019–26. doi:10.1291/hypres.22.161. PMID 9886892.
  19. ↑ Sorour AE, Lönn J, Nakka SS, Nayeri T, Nayeri F (January 2015). "Evaluation of hepatocyte growth factor as a local acute phase response marker in the bowel: the clinical impact of a rapid diagnostic test for immediate identification of acute bowel inflammation". Cytokine. 71 (1): 8–15. doi:10.1016/j.cyto.2014.07.255. PMID 25174881.
  20. ↑ Yang J, Chen S, Huang L, Michalopoulos GK, Liu Y (April 2001). "Sustained expression of naked plasmid DNA encoding hepatocyte growth factor in mice promotes liver and overall body growth". Hepatology. 33 (4): 848–59. doi:10.1053/jhep.2001.23438. PMC 1821076. PMID 11283849.
  21. ↑ Appasamy R, Tanabe M, Murase N, Zarnegar R, Venkataramanan R, Van Thiel DH, Michalopoulos GK (March 1993). "Hepatocyte growth factor, blood clearance, organ uptake, and biliary excretion in normal and partially hepatectomized rats". Laboratory Investigation; A Journal of Technical Methods and Pathology. 68 (3): 270–6. PMID 8450646.
  22. ↑ Kato Y, Liu KX, Nakamura T, Sugiyama Y (August 1994). "Heparin-hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity". Hepatology. 20 (2): 417–24. doi:10.1002/hep.1840200223. PMID 8045504.
  23. ↑ Yu Y, Yao AH, Chen N, Pu LY, Fan Y, Lv L, Sun BC, Li GQ, Wang XH (July 2007). "Mesenchymal stem cells over-expressing hepatocyte growth factor improve small-for-size liver grafts regeneration". Molecular Therapy. 15 (7): 1382–9. doi:10.1038/sj.mt.6300202. PMID 17519892.
  24. ↑ Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW (November 2014). "The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system". The Journal of Pharmacology and Experimental Therapeutics. 351 (2): 390–402. doi:10.1124/jpet.114.218735. PMC 4201273. PMID 25187433.
  25. ↑ Wright JW, Harding JW (2015). "The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease". Journal of Alzheimer's Disease. 45 (4): 985–1000. doi:10.3233/JAD-142814. PMID 25649658.
  26. ↑ Wright JW, Kawas LH, Harding JW (February 2015). "The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases". Progress in Neurobiology. 125: 26–46. doi:10.1016/j.pneurobio.2014.11.004. PMID 25455861.
  27. ↑ Comoglio PM (1993). "Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells". Exs. 65: 131–65. PMID 8380735.
  28. ↑ Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK (October 1991). "Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor". The EMBO Journal. 10 (10): 2867–78. PMC 452997. PMID 1655405.
  29. ↑ Johnson M, Koukoulis G, Kochhar K, Kubo C, Nakamura T, Iyer A (September 1995). "Selective tumorigenesis in non-parenchymal liver epithelial cell lines by hepatocyte growth factor transfection". Cancer Letters. 96 (1): 37–48. doi:10.1016/0304-3835(95)03915-j. PMID 7553606.
  30. ↑ Kochhar KS, Johnson ME, Volpert O, Iyer AP (1995). "Evidence for autocrine basis of transformation in NIH-3T3 cells transfected with met/HGF receptor gene". Growth Factors. 12 (4): 303–13. doi:10.3109/08977199509028968. PMID 8930021.
  31. ↑ 31.0 31.1 Lyon M, Deakin JA, Gallagher JT (January 2002). "The mode of action of heparan and dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor". The Journal of Biological Chemistry. 277 (2): 1040–6. doi:10.1074/jbc.M107506200. PMID 11689562.
  32. ↑ Lyon M, Deakin JA, Rahmoune H, Fernig DG, Nakamura T, Gallagher JT (Jan 1998). "Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate". J Biol Chem. 273 (1): 271–8. doi:10.1074/jbc.273.1.271. PMID 9417075.
  33. ↑ Sergeant N, Lyon M, Rudland PS, Fernig DG, Delehedde M (June 2000). "Stimulation of DNA synthesis and cell proliferation of human mammary myoepithelial-like cells by hepatocyte growth factor/scatter factor depends on heparan sulfate proteoglycans and sustained phosphorylation of mitogen-activated protein kinases p42/44". The Journal of Biological Chemistry. 275 (22): 17094–9. doi:10.1074/jbc.M000237200. PMID 10747885.

Further reading

External links

Retrieved from "https://www.wikidoc.org/index.php?title=Hepatocyte_growth_factor&oldid=1421525"